Breakthroughs in Clinical Diabetes, Obesity and Metabolic Diseases

Dear Colleagues,

Diabetes, obesity, and metabolic diseases continue to pose significant global health challenges, driving the need for groundbreaking therapeutic strategies.

Recent years have seen remarkable breakthroughs in the development of novel drugs, including weekly insulin, dual GLP-1 and GIP receptor agonists, and triple agonists targeting GLP-1, GIP, and glucagon receptors, as well as the emergence of oral GLP-1 receptor agonists. Additionally, advancements in medical technology are revolutionizing treatment approaches, offering new possibilities for managing these conditions more effectively.

Furthermore, precision medicine is playing an increasingly vital role in tailoring treatments based on individual patient characteristics, optimizing therapeutic outcomes.

In light of these exciting developments, we are pleased to introduce this Special Issue, entitled “Breakthroughs in Clinical Diabetes, Obesity and Metabolic Diseases”. We invite researchers and clinicians to contribute original studies, reviews, and case reports exploring the latest advancements in pharmacotherapy, precision medicine, and innovative technologies. We also highly encourage the submission of real-world data demonstrating clinical efficacy and practical applications.

We look forward to receiving your valuable contributions, which will help to shape the future of diabetes, obesity, and metabolic disease management.

Dr. Yuzuru Ohshiro
Prof. Dr. Kunimasa Yagi
Dr. Yasuhiro Maeno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.